PPARs are a family of nuclear hormone receptors involved in various processes that could influence ovarian function. We investigated the cellular localization and expression of PPARs during follicular development in ovarian tissue collected from rats 0, 6, 12, 24, and 48 h post-PMSG. A second group of animals received human CG (hCG) 48 h post-PMSG. Their ovaries were removed 0, 4, 8, 12, and 24 h post-hCG to study the periovulatory period. mRNAs corresponding to the PPAR isotypes (␣, ␦, and ␥) were localized by in situ hybridization. Changes in the levels of mRNA for the PPARs were determined by ribonuclease protection assays.
P
PARs ARE A recently identified family of nuclear hormone receptors belonging to the steroid receptor superfamily (1) . There are three PPAR family members: PPAR␣ (NR1C1), PPAR␦ [␤, NUC-1, fatty acid-activated receptor (FAAR), NR1C2], and PPAR␥ (NR1C3). Each PPAR is transcribed from an individual gene. The gene encoding PPAR␥ gives rise to different species of mRNA resulting from alternate splicing and the use of different promoters (2) (3) (4) .
PPARs are activated by various factors such as fibrates, herbicides, industrial plasticizers, insulin, fatty acids including arachidonic acid and its eicosanoid metabolites, nonsteroidal antiinflammatory drugs, and thiazolidinediones (insulin-sensitizing drugs; see Ref. 1 for a review). The activity of PPARs can also be modulated by phosphorylation (1) . PPARs heterodimerize with 9, cis-retinoic acid receptors and bind to PPAR response elements (PPREs) present in the promoter region of target genes, thereby regulating transcription.
Since their initial discovery, PPARs have been found to be involved in a variety of cellular functions, some which could directly influence ovarian physiology. PPARs can bind to estrogen response elements (5, 6) , inactively occupying the estrogen response element and preventing access to the ER (5) . PPARs also regulate the activity and expression of aromatase, an enzyme involved in the biosynthesis of estrogen. In human breast adipose tissue and granulosa-lutein cells, aromatase activity is inhibited by the activation of PPAR␥ (7, 8) . The activation of PPAR␥ has also been shown to inhibit progesterone production by cultured porcine (9) and human (10) granulosa cells. This effect of PPAR␥ on progesterone production may result from its ability to decrease the activity of 3␤-hydroxysteroid dehydrogenase (9) .
PPARs are capable of modulating the expression and activity of proteolytic enzymes which could affect tissue remodeling and angiogenesis that occurs during ovarian follicular development, ovulation, and luteal formation. For example, PPARs regulate gelatinase B (11-13) and plasminogen activator (14) , proteases known to be stimulated during follicular growth and ovulation. The promoter for another protease, stromelysin, contains a PPRE suggesting that its expression is regulated by PPARs (15) .
Other factors that have been shown to be involved in ovarian function, such as endothelin-1 (16), nitric oxide synthase (17) (18) (19) , and cyclooxygenase-2 (COX-2; 20, 21), are also regulated by PPARs. PPAR␥ decreases the secretion of endothelin-1 from endothelial cells (22) and inhibits the expression of nitric oxide synthase in macrophages (12) and vascular smooth muscle cells (23) . A PPRE has been identified upstream of the COX-2 transcriptional start site (24) , and activation of PPARs modulates the expression of COX-2 (24 -26) . Taken together, these findings indicate that there are a number of ways PPARs could regulate ovarian function.
Abbreviations: COX-2, cyclooxygenase-2; FAAR, fatty acid-activated receptor; hCG, human CG; NR1C1-NR1C, a family of nuclear hormone receptors belonging to the steroid receptor superfamily; PGJ 2 , prostaglandin J 2 ; PPRE, PPAR response elements; PCOS, polycystic ovary syndrome.
All three PPAR isotypes have been identified in the rat ovary (27) , and mRNA for PPAR␥ has been found in the cow (2, 28) and human ovary (29) . However, it is not completely understood where the PPARs are localized and produced in the ovary, how expression of the PPARs changes during the ovarian cycle, how they may be regulated, or their role in ovarian function. The studies described herein were designed to investigate the localization and expression of PPARs in the ovary and their potential to regulate ovarian steroidogenesis. 
Materials and Methods Materials

Animals
All animal procedures were approved by the University of Kentucky Animal Care and Use Committee. Female, Sprague Dawley rats (Harlan Sprague Dawley, Inc., Indianapolis, IN) were injected with 10 IU PMSG sc on d 23 of age to initiate follicular development. At 0 (no PMSG), 6, 12, 24, and 48 h post-PMSG, ovaries were collected from a subset of these animals (n ϭ 3-4/time point) to examine the expression of PPARs during follicular growth. The remaining animals received 10 IU hCG sc 48 h post-PMSG to stimulate ovulation and luteal development. Animals were killed 0 (no hCG), 4, 8, 12 , and 24 h after treatment with hCG (n ϭ 3/time point) and their ovaries collected. Ovaries were frozen in liquid nitrogen and stored at Ϫ70 C until RNA isolation, or placed in OCT and stored at Ϫ70 C until sectioned for in situ hybridization.
Tissues were collected from a second group of animals during follicular development and the periovulatory period to localize mRNA for PPAR␥ and apoptotic cells in adjacent tissue sections. Female Sprague Dawley rats were injected with 10 IU PMSG sc on d 23 of age. Ovaries were collected from a subset of these animals 0 (no PMSG) and 24 h post-PMSG (n ϭ 2/time point). The remaining animals received 10 IU of hCG 48 h post-PMSG. Animals in this latter group were killed 0 (no hCG), 4, and 24 h after treatment with hCG (n ϭ 3/time point) and their ovaries collected. All ovaries were placed in OCT and snap frozen. Tissues were stored at Ϫ70 C until sectioned for in situ hybridization and the detection of apoptotic cells.
To investigate the role of PPAR␥ in steroidogenesis in vitro, granulosa cells were collected from PMSG-primed immature rats. On d 23 of age, female rats received 10 IU PMSG sc; 48 h later, granulosa cells were collected as described previously (30) .
In situ hybridization
Ovaries collected from the first group of animals during follicular development and the periovulatory period were sectioned at 8 m and mounted on ProbeOn Plus slides (Fisher Scientific, Pittsburgh, PA). Tissue sections were fixed in 4% paraformaldehyde, washed twice in PBS (pH 7.6), followed by two washes in 0.75% glycine. Slides were rinsed twice in PBS and then washed in triethanolamine buffer with 0.25% acetic anhydride. Following another PBS wash, sections were dehydrated via passage through a series of alcohol washes.
Sense and antisense riboprobes for PPAR␣, ␦, and ␥ were synthesized using a MAXISCRIPT kit (Ambion, Inc. Austin, TX) and [␣- 33 P]UTP (10 mCi/ml; NEN Life Science Products, Boston, MA). Tissues were hybridized with radiolabeled probe (1 ϫ 10 6 cpm) in 50 l hybridization buffer (100 g/ml salmon sperm DNA, 250 g/ml total yeast RNA, 250 g/ml yeast transfer RNA, 20 mm Tris, 1 mm EDTA, 300 mm NaCl, 50% formamide, 10% dextran sulfate, and 1ϫ Denhart's) at 60 C for 15-18 h. Nonspecifically bound RNA transcripts were removed by washing tissue sections in 2ϫ standard saline citrate (SSC) and treating them with RNase A (0.1 mg/ml) for 30 min at 45 C. Tissue sections were then washed in 0.2ϫ SSC, followed by a 1 h wash in 0.1ϫ SSC at 55 C. After air drying, slides were dipped in Kodak NTB2 emulsion and exposed at 4 C for 4 -6 (PPAR␥) or 6-8 (PPARs ␣ and ␦) wk. Slides were brought to room temperature, developed, and counterstained with hematoxylin.
Ovarian tissue collected from the second group of animals to determine whether expression of PPAR␥ mRNA was correlated with the presence of apoptotic cells was serially sectioned (10 m) and placed on ProbeOn Plus slides. Tissues were processed as described above with the following modification. mRNA corresponding to PPAR␥ was localized using 35 S-labeled riboprobes (10 mCi/ml; ICN Biomedicals, Inc., Irvine, CA).
RNase protection assay
Total RNA was isolated from ovaries collected during follicular development and the periovulatory period using TRIZOL reagent and quantified by spectrophotometry. Plasmids containing rat cDNAs for PPARs ␣, ␦, and ␥, and mouse cDNA for ribosomal protein L32 (the latter kindly provided by Dr. O.-K. Park-Sarge, University of Kentucky, Lexington, KY) were linearized with the appropriate restriction enzymes. Antisense riboprobes were transcribed using Ambion, Inc.'s MAXI-SCRIPT kit and [␣-
32 P]UTP (10 mCi/ml; NEN Life Science Products). RNase protection assays were carried out as described previously (31, 32) using RNA isolated from 3-4 animals/time point (each sample assayed once). Briefly, samples of total RNA (1-6 g) were hybridized for 15-18 h at 50 C with excess radiolabeled antisense riboprobe. Loading variation between samples was standardized by including L32 riboprobe in all hybridization reactions. Protected RNA fragments were analyzed by electrophoresis through a 5% acrylamide/8 m urea gel. Quantification of band intensity in the gels was determined using a phosphor-imager (Molecular Dynamics, Inc., Sunnyvale, CA). The band intensity of mRNA for each PPAR isotype was normalized to the corresponding band for L32 per sample.
Detection of apoptotic cells
Apoptotic cells were identified in serial sections of frozen ovarian tissue (10 m) using ApoAlert (CLONTECH Laboratories, Inc., Palo Alto, CA). The manufacturer's instructions were followed with a few modifications. Tissue sections were allowed to come to room temperature before proceeding with fixation and were not treated with proteinase K. The tissue sections were not stained with propidium iodide, but rather mounted with Vectashield mounting medium (Vector Laboratories, Inc., Burlingame, CA) containing propidium iodide. Three slides/animal with three tissue sections/slide were processed to detect apoptotic cells.
Cell culture
Granulosa cells were pooled and 1 ϫ 10 6 cells cultured per ml of DMEM-Ham's F-12 containing 1% BSA, 0.01% pyruvic acid, 0.22% bicarbonate, and ITS (insulin, transferrin, selenium) at 37 C in an atmosphere of 95% O 2 :5% CO 2 . Depending on the number of cells collected, cultured cells were treated in duplicate or triplicate as follows (n ϭ 5 independent experiments): control, ciglitazone (25 and 50 m), or PGJ 2 (10 and 25 m). Treatments were added to the cells at the time of plating. Forty-eight hours after the initiation of culture, media were collected to measure the concentrations of E2 and progesterone by RIA. Cell viability was assessed at the end of culture by extracting and analyzing total cellular RNA in formaldehyde/agarose gel.
RIA
Concentrations of E2 and progesterone were determined in culture media by using Coat-A-Count tubes (Diagnostic Products Co., Los Angeles, CA), which are direct, solid phase 125 I RIA kits. These kits are designed to determine concentrations of steroids in serum, and our laboratory has verified their ability to measure levels of steroids in conditioned culture media (data not shown). Assay sensitivity is 0.03 ng/ml for progesterone and 50 pg/ml for E2. The inter and intraassay coefficients of variation were 7.9% and 5.9% for progesterone, and 4.8% and 3.6% for E2, respectively.
Statistical analysis
Levels of mRNA for the PPAR isotypes in ovarian tissue collected during follicular development and the periovulatory period were analyzed by one-way ANOVA. Posthoc comparisons were made using Tukey's HSD. Concentrations of progesterone and E2 in conditioned culture media were subjected to square root transformation before being analyzed by one-way ANOVA. Posthoc comparisons were made using the Student-Newman-Kuels test. A P Ͻ 0.05 was considered significant.
Results
mRNAs for the PPAR isotypes were localized in ovarian tissue using in situ hybridization. As can be seen in Figs. 1 and  2 , mRNA for PPAR␥ is limited primarily to granulosa cells throughout follicular development and the periovulatory period. A few follicles in some of the animals contained theca extema that labeled weakly for PPAR␥ mRNA, but no consistent pattern was observed (date not shown). During follicular development (Fig. 1) , granulosa cells in the majority of follicles expressed high levels of mRNA for PPAR␥ at all time points studied before and after PMSG administration.
However, the granulosa cells in some follicles were less intensely labeled than others.
During the periovulatory period, the expression of mRNA for PPAR␥ in granulosa cells decreased after the administration of hCG (Fig. 2) . The expression pattern at 0 h (48 h post-PMSG, no hCG) was very similar to the pattern seen during follicular development, with granulosa cells in most follicles labeled intensely for PPAR␥ mRNA (Fig. 2, a and g ). By 4 h post-hCG, granulosa cells in a number of large follicles lost expression of mRNA for PPAR␥. Interestingly, the expression of mRNA for PPAR␥ did not decrease uniformly in all follicles; rather some follicles lost expression, whereas others maintained high expression (Fig. 2, b and h) . At 24 h post-hCG, PPAR␥ expression in luteinizing granulosa cells was undetectable, but labeling remained high in follicles (Fig.  2, c and i) .
In contrast to the expression of mRNA for PPAR␥, mRNA for both PPAR␣ and ␦ was expressed primarily in theca and stroma tissues. The expression patterns of PPAR␣ and ␦ did not change during follicular development or the periovulatory period; therefore, only the representative time point of 48 h post-PMSG is shown ( Fig. 3 and 4, respectively) . As can be seen in Fig. 3 , the expression of mRNA for PPAR␣ was low, not much higher than background. Labeling of mRNA for PPAR␦, although seen throughout the tissue, was more intense in theca and interstitial tissues than in granulosa cells (Fig. 4) .
To quantify the change in levels of mRNA for the PPAR isotypes during both follicular development and the periovulatory period, RNase protection assays were conducted. Confirming the expression pattern seen with in situ hybridization, data from RNase protection assays show that the levels of mRNA for PPAR␣ and ␦ remained steady throughout follicular development and the periovulatory period (Figs. 5 and 6, respectively). The level of mRNA for PPAR␥ also remained steady during follicular development (Fig. 5) . However, by 4 h post-hCG, there was a significant decrease in the levels of mRNA for PPAR␥ (P Ͻ 0.05; Fig. 6 ). The level of mRNA for PPAR␥ remained low and at 24 h post-hCG levels were reduced by 64% compared with those at 0 h (P Ͻ 0.01).
Because granulosa cells in some follicles labeled more intensely for PPAR␥ mRNA than others during follicular development, and the finding that some ovarian structures maintained expression for PPAR␥ mRNA 24 h post-hCG, we hypothesized that the expression of mRNA for PPAR␥ may be related to follicular health. To test this idea, ovarian tissue was collected from a second group of animals during follicular development and the periovulatory period. mRNA for PPAR␥ and the presence of apoptotic cells were identified in serial tissue sections.
As seen in tissue collected from the first group (Fig. 1) , the majority of follicles in tissue collected from animals in the second group 0 and 24 h post-PMSG contained granulosa cells expressing mRNA for PPAR␥ (data not shown). However, few follicles contained apoptotic cells in ovaries from the second group of animals, and there was no correlation between the labeling intensity of mRNA for PPAR␥ and the presence of apoptotic cells (data not shown). The same trend was observed during the periovulatory period. Tissue collected 4 h post-hCG are presented in Fig. 7 and represent the findings in periovulatory tissues. There was no relationship between the relative level of PPAR␥ mRNA expression and the presence or absence of apoptotic cells.
The significant decline in PPAR␥ expression after the administration of hCG led us to hypothesize that this PPAR isotype may be involved in the periovulatory shift in steroid production from E2 to progesterone. To begin testing this hypothesis, granulosa cells were cultured in the presence and absence of PGJ 2 (10 and 25 m; an endogenous activator of PPAR␥; 33) and ciglitazone (25 and 50 m; a member of the thiazolidinedione drug family that specifically activates PPAR␥).
The addition of PGJ 2 to cultured rat granulosa cells resulted in a dose-dependent increase in progesterone secretion (Fig. 8A ). There was a 3-fold increase in basal progesterone secretion when cells were treated with 10 m PGJ 2 . In the presence of 25 m PGJ 2 , progesterone secretion increased 14-fold (P Ͻ 0.05). However, only the high dose of ciglitazone (50 m) resulted in a significant, 3-fold increase in progesterone secretion (P Ͻ 0.05). Basal E2 secretion was stimulated by the high dose of each PPAR␥ agonist (Fig. 8B) . Treatment with 25 m PGJ 2 and both 25 and 50 m ciglitazone resulted in a significant 30% increase in E2 secretion (P Ͻ 0.05).
Discussion
Since the initial discovery of a PPAR in mouse liver (34) and the subsequent identification of two additional family members, the PPARs have been found to be important factors regulating a multitude of cellular activities in a variety of tissues. PPAR␥ has been reported to be expressed in ovarian tissue from humans (29) and cattle (2, 28) , and all three PPAR isotypes have been identified in ovarian tissue taken from an adult rat (27) . The data presented here extend those initial findings by characterizing the expression of each PPAR throughout follicular development and the periovulatory period in the rat. Our findings show that the expression of PPAR␥ is restricted primarily to granulosa cells of developing follicles, whereas mRNAs for PPAR␣ and ␦ were local- ized to the theca and stroma. The high expression of mRNA for PPAR␥ both before and after the administration of PMSG suggests that this isotype may play a role in follicular development. Of particular interest was the observation that levels of mRNA for PPAR␥ decreased in response to treatment with hCG, which mimics the LH surge. This finding indicates that PPAR␥ may be inhibitory to the transition of granulosa cells into luteal cells. In contrast to the expression of PPAR␥, the steady expression of mRNAs for PPAR␣ and ␦ throughout follicular development and the periovulatory period, coupled with their more general distribution throughout ovarian tissue, suggests that these two PPARs may be important factors in maintaining basal ovarian function.
Although the granulosa cells in the majority of follicles were labeled for PPAR␥ mRNA during follicular development, some follicles were more intensely labeled than others. A difference in follicular PPAR␥ labeling was also seen during the periovulatory period. The decrease in granulosa cell PPAR␥ expression in response to gonadotropin treatment did not occur uniformly in all follicles; rather, some follicles lost expression whereas others maintained high levels of expression, even 24 h post-hCG. This finding led us to hypothesize that PPAR␥ expression may relate to follicular health. However, the lack of association between the expression of mRNA for PPAR␥ and the presence of apoptotic cells in follicles during follicular development and the periovulatory period indicate that PPAR␥ expression is not correlated with cellular health. Another possible explanation for the difference in PPAR␥ expression between granulosa cells in different follicles is that the follicles with lower expression are not as far along the developmental pathway as others in their cohort. This latter hypothesis is currently under investigation.
In our culture system, activation of PPAR␥ in rat granulosa cells resulted in an increase in both progesterone and E2 secretion. These findings differ from previous reports of PPAR␥ inhibiting steroidogenesis in cultured human and porcine granulosa cells (7, 9, 10) . In those studies, the activation of PPAR␥ inhibited progesterone (9, 10) and E2 production (7) . The apparent dichotomy between our findings with rat ovarian cells and those in human and pig ovarian cells could result from the stage of cellular differentiation and/or species variation. Another possible explanation may be the fact that in the current study the steroid content of conditioned media was measured 48 h after the initiation of culture. Because the granulosa cells were collected at a time when they express high levels of mRNA for PPAR␥ ( Fig. 2 ; 48 h post-PMSG), the activation of PPAR␥ in these cells in vitro could initially have had a stimulatory effect on E2 secretion. Because granulosa cells spontaneously luteinize when placed in culture, treatment with PPAR␥ agonists could have augmented progesterone production late in the culture period. Data to support this hypothesis comes from a study by Lö hrke, et al. (1998) . Mid-cycle bovine luteal cells cultured in the presence of PGJ 2 or ciglitazone increased progesterone production (28) . In addition, putative inhibition of PPAR␥ expression by treating bovine luteal cells with aurintricarboxylic acid, resulted in decreased progesterone secretion (28) .
There are a number of studies demonstrating that troglitazone, a member of the thiazolidinedione drug family that is capable of activating PPAR␥, is an effective treatment for some women with polycystic ovary syndrome (PCOS). PCOS is a leading cause of infertility in premenopausal women and is characterized by hyperandrogenism, anovulation, and frequently insulin resistance. Treatment of these women with troglitazone reduced androgen levels, improves hyperinsulinemia, and in some women restored ovulation (35) (36) (37) (38) . These findings suggest that PPAR␥ activity can influence thecal androgen production. Such an activity of PPAR␥ would be interesting because this factor has already been shown to influence granulosa cell steroid production, and we have localized mRNA for PPAR␥ primarily to granulosa cells. Whether our data reflect a species difference between the rat and human, or a difference in expression between gonadotropin-treated and naturally cycling animals is the focus of current and future studies. Results from such studies will yield important information concerning not only how PPARs may influence ovarian function, but also how drugs in clinical use (thiazolidinediones and fibrates) impact ovarian physiology.
In summary, the data presented here show that PPAR␥ is expressed in the ovary, primarily in the granulosa cells of developing follicles. Following the LH surge, levels of FIG. 8 . A, Concentrations of progesterone (ng/ml) in conditioned media from rat granulosa cells cultured for 48 h as described in Materials and Methods (n ϭ 5 independent experiments). B, Concentrations of E2 (pg/ml) in conditioned media from rat granulosa cells cultured for 48 h as described in Materials and Methods (n ϭ 5 independent experiments). Cntrl, Control, Cig, ciglitazone. *, Significantly different from control (P Ͻ 0.05).
mRNA for PPAR␥ decline, indicating that this factor may play a role in follicular development, and/or be inhibitory to the transition of granulosa cells into luteal cells. We have also shown that activation of PPAR␥ in cultured granulosa cells can stimulate the secretion of both progesterone and E2. Further investigation of this PPAR isotype in ovarian function will lead to a better understanding of follicular growth and differentiation, steroidogenesis, as well as the regulation of ovarian gene expression by the gonadotropin surge.
